Treatment of invasive fungal infections in renally impaired patients with amphotericin B colloidal dispersion (Q33691165)

28 July 2017

Treatment of invasive fungal infections in renally impaired patients with amphotericin B colloidal dispersion (English)

1 reference

invasive fungal infections

28 July 2017

1 reference

1 reference

E J Anaissie

1

1 reference

28 July 2017

G N Mattiuzzi

2

1 reference

28 July 2017

C B Miller

3

1 reference

28 July 2017

G A Noskin

4

1 reference

28 July 2017

M J Gurwith

5

1 reference

28 July 2017

R D Mamelok

6

1 reference

28 July 2017

L A Pietrelli

7

1 reference

28 July 2017

language of work or name

English

0 references

publication date

1 March 1998

1 reference

Antimicrobial Agents and Chemotherapy

28 July 2017

1 reference

28 July 2017

42

1 reference

28 July 2017

3

1 reference

28 July 2017

606-611

1 reference

Therapeutic outcome in invasive aspergillosis

28 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=105506

Phase I study of amphotericin B colloidal dispersion for the treatment of invasive fungal infections after marrow transplant

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=105506

Invasive candidiasis during granulocytopenia.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=105506

Dose-dependent antifungal activity and nephrotoxicity of amphotericin B colloidal dispersion in experimental pulmonary aspergillosis

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=105506

Empiric amphotericin B therapy in patients with acute leukemia

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=105506

Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=105506

Amphotericin B revisited: reassessment of toxicity

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=105506

Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=105506

Drug-induced nephrotoxicity. Aetiology, clinical features and management

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=105506

Single-dose pharmacokinetics and tolerance of a cholesteryl sulfate complex of amphotericin B administered to healthy volunteers

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=105506

Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=105506

Comparison of antifungal activity of amphotericin B deoxycholate suspension with that of amphotericin B cholesteryl sulfate colloidal dispersion

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=105506

Efficacy and safety of amphotericin B colloidal dispersion compared with those of amphotericin B deoxycholate suspension for treatment of disseminated murine cryptococcosis

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=105506

Evaluation of new antifungal drugs for the treatment of systemic fungal infections. Infectious Diseases Society of America and the Food and Drug Administration

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=105506

Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=105506

The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=105506

Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients

30 October 2018

1 reference

12 December 2020

Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS

1 reference

12 December 2020

NEPHROTOXICITY OF AMPHOTERICIN B; EARLY AND LATE EFFECTS IN 81 PATIENTS

1 reference

12 December 2020

Empiric antifungal therapy in febrile granulocytopenic patients. EORTC International Antimicrobial Therapy Cooperative Group

1 reference

12 December 2020

Identifiers

0 references

1 reference

28 July 2017

1 reference